Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-194-5 | CAS number: 2385-77-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Remarks:
- The test substance (Citronellal; CAS 106-23-0) represents the racemate of the registered substance (R)-3,7-dimethyloct-6-enal (CAS 2385-77-5).
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
Test material
- Reference substance name:
- Citronellal
- EC Number:
- 203-376-6
- EC Name:
- Citronellal
- Cas Number:
- 106-23-0
- Molecular formula:
- C10H18O
- IUPAC Name:
- 3,7-dimethyloct-6-enal
- Details on test material:
- - Name of test material (as cited in study report): citronellal (3,7-dimethyl-6-octenal)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: HAGEMANN
- Weight at study initiation: 220 g (male); 170 g (female)
- Fasting period before study: 15 - 20 hours
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: from 21.5 to 50 %
- Amount of vehicle (if gavage): 10 ml/kg bw
MAXIMUM DOSE VOLUME APPLIED: 5000 mg/kg
DOSAGE PREPARATION (if unusual): administered as a 30 % aqueous emulsion in carboxymethylcellulose containing 1-2 drops of CREMOPHOR EL
- Doses:
- 2150; 2610; 3160; 3830; 5000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: day 2-4, day7, day 13 (weighing); 1 h, 2 h, 4 h, 5 h, and then daily on working days till the end of the study (clinical observations)
- Necropsy of survivors performed: yes - Statistics:
- Industrial hygiene orientating investigation (1980): FINNEY, D.J., Probitanalysis, Cambridge University Press, 3. Edition, 1971; all doses investigated used for calculation; test on homogeneity: CHI**2-value: 5.28 degree of freedom: 3; CHI**2 probability: 84.74 % homogeneity: acceptable confidence limit 95% (LD50 dose 2555 mg/kg bw) lower: 422 upper: 3307
Evaluation of data (1981): Interpolation of LD50 using the respective dosing groups leading to a mortality close to 50% (male LD50: two dosing groups; female LD50: one dosing group; male/female LD50: two dosing groups; based on original data from 1980).
Results and discussion
Effect levelsopen allclose all
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 423 mg/kg bw
- Remarks on result:
- other: interpolation from two dosing groups (1981)
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 555 mg/kg bw
- Remarks on result:
- other: including all dosing groups (1980)
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 150 mg/kg bw
- Remarks on result:
- other: including one dosing group (1981)
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 872 mg/kg bw
- Remarks on result:
- other: interpolation from two dosing groups (1981)
- Gross pathology:
- deceased animals: heart: acute atrial dilatation, acute venous congestion; liver: yellow confluent peripheral liver lobes
survivors: thickened gastroesophageal vestibule tip; single adhesions of liver and gastroesophageal vestibule; no findings in 2610 and 2150 mg/kg dosing groups.
Any other information on results incl. tables
Table 1: Acute toxicity - mortality
dose (mg/kg) |
5000 |
3830 |
3160 |
2610 |
2150 |
|||||
sex |
m |
f |
m |
f |
m |
f |
m |
f |
m |
f |
number of animals |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
5 |
deceased animals within 1 hour |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
on day 1 |
3 |
4 |
1 |
4 |
3 |
3 |
2 |
3 |
0 |
2 |
on day 2 |
3 |
5 |
1 |
4 |
3 |
5 |
2 |
3 |
0 |
2 |
on day 7 |
3 |
5 |
1 |
5 |
3 |
5 |
2 |
5 |
0 |
2 |
on day 14 |
3 |
5 |
1 |
5 |
3 |
5 |
2 |
5 |
0 |
2 |
overall |
3/5 |
5/5 |
1/5 |
5/5 |
3/5 |
5/5 |
2/5 |
5/5 |
0/5 |
2/5 |
mean body weight gain in 13 days (g) |
82 |
- |
72 |
- |
71 |
- |
71 |
- |
94 |
35 |
Table 2: Acute toxicity - clinical symptoms
dose (mg/kg) |
5000 |
3830 |
3160 |
2610 |
2150 |
dyspnoea |
*** |
*** |
*** |
*** |
*** |
apathy |
*** |
*** |
*** |
*** |
*** |
abnormal position |
*** |
*** |
*** |
*** |
*** |
tumbling |
*** |
*** |
*** |
*** |
*** |
atony |
*** |
*** |
|||
paresis hindlimb |
*** |
*** |
|||
pain reflex absence |
*** |
||||
cornea reflex absence |
*** |
||||
anaesthesia-like state |
*** |
||||
tremor |
*** |
||||
convulsions |
*** |
||||
spasmic gait |
*** |
*** |
|||
fibrillar convulsions |
*** |
*** |
*** |
||
clonic cramps |
*** |
||||
scrubby coat |
*** |
*** |
*** |
*** |
*** |
erythema |
*** |
*** |
*** |
||
exsiccosis |
*** |
*** |
*** |
*** |
|
clotted eyes |
*** |
||||
stretching cramps |
*** |
||||
fascic convulsions |
*** |
*** |
*** |
*** |
|
poor general condition |
*** |
*** |
*** |
*** |
*** |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.